Сравнение

Maridebart Cafraglutide vs. VK2735

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Метаболизм

Номер CAS

нет данных

Молекулярная масса

нет данных

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Maridebart Cafraglutide

MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Maridebart Cafraglutide	VK2735
Германия	Не одобрено	Не одобрено
США	Не одобрено	Не одобрено

Полные записи

Maridebart Cafraglutide

Полная запись →

VK2735

Полная запись →

Frequently asked questions

What is the difference between Maridebart Cafraglutide and VK2735?: Maridebart Cafraglutide is classified as "Метаболизм", while VK2735 is classified as "Метаболизм". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Maridebart Cafraglutide or VK2735?: The highest available evidence level is "РКИ на людях" for Maridebart Cafraglutide and "РКИ на людях" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Maridebart Cafraglutide and VK2735 in Germany and the United States?: Германия: Maridebart Cafraglutide — Не одобрено, VK2735 — Не одобрено. США: Maridebart Cafraglutide — Не одобрено, VK2735 — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

Maridebart Cafraglutide

VK2735

Германия

Не одобрено

США

Не одобрено

Frequently asked questions

What is the difference between Maridebart Cafraglutide and VK2735?

Maridebart Cafraglutide is classified as "Метаболизм", while VK2735 is classified as "Метаболизм". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Maridebart Cafraglutide or VK2735?

The highest available evidence level is "РКИ на людях" for Maridebart Cafraglutide and "РКИ на людях" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Maridebart Cafraglutide and VK2735 in Germany and the United States?

Германия: Maridebart Cafraglutide — Не одобрено, VK2735 — Не одобрено. США: Maridebart Cafraglutide — Не одобрено, VK2735 — Не одобрено. These are factual summaries with source and review date on the individual pages.